Gastro Entero Pancreatic Neuroendocrine Tumors
Also known as: Gastroenteropancreatic Neuroendocrine Tumor Disease / Gastroenteropancreatic Neuroendocrine Tumors / Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET) / Gastroenteropancreatic Neuroendocrine Tumor / Gastroenteropancreatic Neuroendocrine Tumours / Gastroenteral-Pancreatic Neuroendocrine Tumors / Neuroendocrine Tumors,Gastroenteropancreatic / Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) / Gastro-Entero-Pancreatic Tumors (GEPs) / Gastro-enteropancreatic Neuroendocrine Tumor / GEP-NET / Gastro-entero-pancreatic Neuroendocrine Tumors / Neuroendocrine Gastroenteropancreatic Tumour / Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) / Gastro-entero Pancreatic Neuroendocrine Tumors / Gep Net / Gastroenteropancreatic neuroendocrine tumour disease
Drug | Drug Name | Drug Description |
---|---|---|
DB13985 | Lutetium Lu 177 dotatate | A radiolabeled somatostatin analog used to treat somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors. |
DB12602 | Pentetreotide | A somatostatin receptor inhibitor, available in a kit with Indium-111, used as a contrast agent in the visualization of somatostatin receptor-positive neuroendocrine tumours. |